Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


With Resolution of Fee-Sharing Dispute, Settlement Funding is Now Available to Avandia Plaintiffs' Attorneys

CRESSKILL, N.J., Feb. 14, 2013 /PRNewswire/ -- Attorneys representing plaintiffs suing GlaxoSmithKline (GSK) over the drug Avandia's side effects have resolved their dispute about sharing fees of $142 million. Over 50,000 lawsuits were filed in US state and federal courts citing GlaxoSmithKline's failure to inform type-2-diabetes patients about Avandia's potentially life-threatening side effects: heart attack and failure, stroke, bone fractures, vision loss, and death. The litigation has taken over ten years, with the lead attorneys alone logging more than 60,000 hours. Yet none of the plaintiffs' attorneys have received any compensation for their time or out-of-pocket expenses. RD Legal Funding is now making immediate post-settlement financing available to ease the Avandia plaintiffs' attorneys' financial burdens. 

(Photo: http://photos.prnewswire.com/prnh/20110803/NY45278LOGO)

The FDA approved the use of rosiglitazone—marketed as Avandia—for the treatment of type-2-diabetes in 1999. Tens of millions of prescriptions were written for the drug which may have caused between 60,000 and 200,000 heart attacks and deaths due to cardiovascular problems in the US alone.

  • 2001: GSK receives an FDA reprimand letter regarding false and misleading comments made by sales representatives about Avandia to an undercover investigator.
  • 2005: GSK's draft analysis of Avandia clinical data indicates heart risks. The company modifies Avandia labels, but the warnings are not prominently displayed and do not adequately convey potential health hazards.
  • 2007:  The New England Journal of Medicine reports that Avandia users face a 43 percent higher risk of heart attack or other cardiovascular events and over 60% increase in the risk of cardiovascular death. Avandia profits in 2007 are $3.2 billion.
  • 2007: Congressional hearings review when information about Avandia heart attack risks was available and why it was not disclosed to the public earlier. The FDA mandates a black box warning about Avandia heart attack risks.
  • 2008: An FDA report implicates Avandia in an estimated 83,000 heart attacks.
  • September 2010: Avandia is banned in several European countries but remains on the US market.
  • 2010: GSK pays a $2.36 billion charge to settle 10,000 of 13,000 Avandia US civil lawsuits, investigations over its antidepressant Paxil, and manufacturing problems in its Puerto Rico plant.
  • November 2011: GSK agrees to pay the US government $3 billion to resolve civil and criminal investigations alleging that the company had paid doctors and manipulated medical research to promote Avandia. A mediator is appointed to resolve the bulk of the pending MDL cases.
  • January 2012: A committee of eight Avandia plaintiffs' attorneys is charged with drafting the fee allocation plan for 58 lawyers and firms, with the total amount to be distributed set at 6.25 percent of the total settlement.
  • July 2012: GSK pleads guilty to withholding safety data on Avandia.
  • November 2012: GSK agrees to pay $90 million to settle the claims of 37 states and the District of Columbia.
  • November 2012: The committee submits its fee-sharing agreement which is disputed by nine attorneys. Bruce P. Merenstein is appointed as special master. 
  • January 22, 2013: A modified plan, agreed to by the nine objectors, is filed in PA federal court.

Avandia plaintiffs' attorneys are urged to contact RD Legal Funding, whose unique fee acceleration program will provide them with settlement financing within several days, with no monthly interest or principal payments, as well as no upfront points or fees. No payment of any kind is required until the attorney's settlement fee is received. RD Legal Funding is one of the nation's leading providers of post-settlement financing. For more information call 800-565-5177 or visit http://www.legalfunding.com.

SOURCES:
http://topics.nytimes.com/top/news/health/diseasesconditionsandhealthtopics/avandiadrug/index.html
http://www.drugwatch.com/avandia/lawsuit.php
http://www.bloomberg.com/news/2013-01-18/glaxo-accord-said-to-spur-lawyer-fight-over-fees.html
http://www.legalfunding.com/blog/settlement-funding-for-avandia-plaintiffs-attorneys/

SOURCE RD Legal Funding

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
Code-named “Fox Fur”, the twenty-third release of OpenNebula is available today with complete support to build clouds on existing VMware environments. OpenNebula 4.10 seamlessly integrates vCenter virtualized infrastructures leveraging the advanced features such as vMotion, HA or DRS s...
The OpenNebula Project has just announced the Beta release of vOneCloud, a CentOS Linux virtual appliance for vSphere that contains all required OpenNebula services optimized to work on existing VMware vCenter deployments. vOneCloud is for companies that want to create a self-service c...
Let’s say we developed an application and plan to move our app to production on Amazon Elastic Cloud (EC2). Our application, in the form of a webapp, was developed using eclipse and we have tested it on Tomcat running locally. Now, we may want to test our app on an EC2 environment befo...
"Our premise is Docker is not enough. That's not a bad thing - we actually love Docker. At ActiveState all our products are based on open source technology and Docker is an up-and-coming piece of open source technology," explained Bart Copeland, President & CEO of ActiveState Software,...
This past week the Appcore team got the opportunity to attend one of the industry’s leading cloud events, Cloud Expo in Santa Clara, CA. We spent a lot of time interacting with attendees at the exhibit portion of the event. As a software company with a sole commitment to CloudStack, we...
As cloud gives an opportunity to businesses to buy services externally – how is cloud impacting your customers? In his General Session at 15th Cloud Expo, Fabio Gori, Director of Worldwide Cloud Marketing at Cisco, provided answers to big questions: Do you see hybrid cloud as where th...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE